Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate‐to‐severe psoriasis patients: 12‐week results from two phase III trials
C. Paul; L. Guenther; H. Torii; H. Sofen; R. Burge; C.Y. Lin; A. Potts Bleakman; L. Mallbris; Y. Poulin
Author Information: Dermatology Department
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.